The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.

AusPAR: Blinatumomab

Australian Public Assessment Report

AusPAR

AusPAR: Blinatumomab [PDF, 1.3 MB]

AusPAR: Blinatumomab [Word, 1.81 MB]

Attachment: Product Information: Blinatumomab [PDF, 690.56 KB]

Attachment: Product Information: Blinatumomab [Word, 788.73 KB]

Attachment: Extract from the Clinical Evaluation Report for Blinatumomab [PDF, 3.99 MB]

Attachment: Extract from the Clinical Evaluation Report for Blinatumomab [Word, 6.8 MB]

Device/Product Name

Blincyto

Active ingredients

Blinatumomab

AusPAR Date

30 September 2019

Published

23 October 2019

Submission Number

PM-2017-01431-1-4

Submission Type

Extension of indications

Decision

Approved